Biomarkers in cancer immunotherapy

Ton N Schumacher; Can Kesmir; Marit M van Buuren

doi:10.1016/j.ccell.2014.12.004

Biomarkers in cancer immunotherapy

Ton N Schumacher, Can Kesmir, Marit M van Buuren

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay systems that interrogate other aspects of the cancer-immunity cycle.

Original language	English
Pages (from-to)	12-14
Number of pages	3
Journal	Cancer Cell
Volume	27
Issue number	1
DOIs	https://doi.org/10.1016/j.ccell.2014.12.004
Publication status	Published - 12 Jan 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ccell.2014.12.004

biomarkersFinal published version, 632 KBLicence: Taverne

Cite this

@article{e6c35cccd8c042d9a81b9f421774de99,

title = "Biomarkers in cancer immunotherapy",

abstract = "Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay systems that interrogate other aspects of the cancer-immunity cycle.",

author = "Schumacher, {Ton N} and Can Kesmir and {van Buuren}, {Marit M}",

year = "2015",

month = jan,

day = "12",

doi = "10.1016/j.ccell.2014.12.004",

language = "English",

volume = "27",

pages = "12--14",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - Biomarkers in cancer immunotherapy

AU - Schumacher, Ton N

AU - Kesmir, Can

AU - van Buuren, Marit M

PY - 2015/1/12

Y1 - 2015/1/12

N2 - Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay systems that interrogate other aspects of the cancer-immunity cycle.

AB - Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay systems that interrogate other aspects of the cancer-immunity cycle.

U2 - 10.1016/j.ccell.2014.12.004

DO - 10.1016/j.ccell.2014.12.004

M3 - Article

C2 - 25584891

SN - 1535-6108

VL - 27

SP - 12

EP - 14

JO - Cancer Cell

JF - Cancer Cell

IS - 1

ER -

Biomarkers in cancer immunotherapy

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this